Asia FX dithers as dollar steadies before Powell speech; yen muted after CPI data
Artivion (NASDAQ:AORT) President and CEO James P. Mackin sold 12,500 shares of common stock on August 15, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sale comes as the stock trades near its 52-week high of $43.97, having delivered impressive returns of nearly 70% over the past year. According to InvestingPro, technical indicators suggest the stock is currently in overbought territory. The shares were sold at a weighted average price of $42.319, for a total transaction value of $528,987.
The prices for the sale ranged from $42.25 to $42.585. Following the transaction, Mackin directly owns 852,783 shares of Artivion.
In other recent news, Artivion Inc. reported strong second-quarter earnings, with revenues reaching $113 million. This figure surpassed consensus projections of $108 million and demonstrated a 14% year-over-year growth. The company’s adjusted EBITDA also outperformed expectations, coming in at $24.8 million against a consensus estimate of $21.1 million. Following these results, several analyst firms have updated their outlooks on Artivion. Stifel raised its price target to $40, while Needham increased it to $45, both maintaining a Buy rating. Canaccord Genuity also adjusted its target to $41, citing the robust quarterly performance. Oppenheimer, despite lowering its target from $42 to $40, maintained an Outperform rating. These developments highlight Artivion’s successful launch of its AMDS stent and stent-graft product, contributing significantly to the revenue growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.